Preemptive Bone Marrow Transplantation and Event-Free Survival in Fanconi Anemia

Overview

Journal Biol Blood Marrow Transplant

Date 2016 Jun 28

PMID 27345141

Citations 12

Authors

Nicholas E Khan

Philip S Rosenberg

Blanche P Alter

Affiliations

Soon will be listed here.

Abstract

Fanconi anemia (FA) is a rare inherited bone marrow failure syndrome associated with high risks of severe bone marrow failure (BMF), acute myeloid leukemia (AML), and solid tumors (ST). Bone marrow transplantation (BMT) provides a theoretical cure for hematologic risks (BMF, AML), but it introduces uncertain risks of transplantation-related mortality (TRM) and carcinogenicity. We developed a mathematical (Markov) decision model to estimate event-free survival (EFS) conditional on age based on per-year cause-specific hazard rates. We assumed that preemptive (PE) BMT eliminates the risks of BMF and AML, but it may introduce independent risks of TRM or influence the trajectory to ST. Our model suggested that the expected mean EFS in FA is higher for PE-BMT at young ages, with minimal risk of TRM and with little carcinogenicity. PE-BMT in adults decreased expected EFS because of the greater competing risk of ST in adulthood. Estimates of EFS conditioned on attained age may be used in shared decision-making when clinicians must counsel patients using limited data. Our methods may be used to model early transplantation in other blood disorders for which hematopoietic stem cell transplantation mitigates some but not all of the risks.

Citing Articles

Hematopoiesis after anti-CD117 monoclonal antibody treatment in the settings of wild-type and Fanconi anemia mice.

Denis M, Swartzrock L, Willner H, Bubb Q, Haslett E, Chan Y Haematologica. 2024; 109(9):2920-2929.

PMID: 38572555 PMC: 11367201. DOI: 10.3324/haematol.2023.284275.

Minimal intensity conditioning strategies for bone marrow failure: is it time for "preventative" transplants?.

Agarwal S Hematology Am Soc Hematol Educ Program. 2023; 2023(1):135-140.

PMID: 38066900 PMC: 10727038. DOI: 10.1182/hematology.2023000470.

The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency.

Santiago M, Liquori A, Such E, Zuniga A, Cervera J Cancers (Basel). 2023; 15(5).

PMID: 36900380 PMC: 10000430. DOI: 10.3390/cancers15051590.

Management of oral leukoplakia in patients with Fanconi anemia.

Pippi R, Di Gioia C, La Rocca U, Bellisario A, Iori A J Oral Maxillofac Pathol. 2022; 26(Suppl 1):S133-S138.

PMID: 35450226 PMC: 9017844. DOI: 10.4103/jomfp.jomfp_280_21.

Genotype-phenotype and outcome associations in patients with Fanconi anemia: the National Cancer Institute cohort.

Altintas B, Giri N, McReynolds L, Best A, Alter B Haematologica. 2022; 108(1):69-82.

PMID: 35417938 PMC: 9827153. DOI: 10.3324/haematol.2021.279981.

References

Alter B, Giri N, Savage S, Peters J, Loud J, Leathwood L . Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol. 2010; 150(2):179-88. PMC: 3125983. DOI: 10.1111/j.1365-2141.2010.08212.x. View

Kutler D, Patel K, Auerbach A, Kennedy J, Lach F, Sanborn E . Natural history and management of Fanconi anemia patients with head and neck cancer: A 10-year follow-up. Laryngoscope. 2015; 126(4):870-9. PMC: 4803627. DOI: 10.1002/lary.25726. View

Rosenberg P, Alter B, Bolyard A, Bonilla M, Boxer L, Cham B . The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006; 107(12):4628-35. PMC: 1895804. DOI: 10.1182/blood-2005-11-4370. View

Shimamura A, Alter B . Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 2010; 24(3):101-22. PMC: 3733544. DOI: 10.1016/j.blre.2010.03.002. View

Khan N, Rosenberg P, Lehmann H, Alter B . Preemptive Bone Marrow Transplantation for FANCD1/BRCA2. Biol Blood Marrow Transplant. 2015; 21(10):1796-801. PMC: 4568159. DOI: 10.1016/j.bbmt.2015.07.006. View

Tamary H, Nishri D, Yacobovich J, Zilber R, Dgany O, Krasnov T . Frequency and natural history of inherited bone marrow failure syndromes: the Israeli Inherited Bone Marrow Failure Registry. Haematologica. 2010; 95(8):1300-7. PMC: 2913078. DOI: 10.3324/haematol.2009.018119. View

Inamoto Y, Shah N, Savani B, Shaw B, Abraham A, Ahmed I . Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant. 2015; 50(8):1013-23. PMC: 4989866. DOI: 10.1038/bmt.2015.63. View

Hutson S, Han P, Hamilton J, Rife S, Al-Rahawan M, Moser R . The use of haematopoietic stem cell transplantation in Fanconi anaemia patients: a survey of decision making among families in the US and Canada. Health Expect. 2013; 18(5):929-41. PMC: 3766454. DOI: 10.1111/hex.12066. View

Rosenberg P, Socie G, Alter B, Gluckman E . Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood. 2004; 105(1):67-73. DOI: 10.1182/blood-2004-04-1652. View

10.

Meier E, Dioguardi J, Kamani N . Current attitudes of parents and patients toward hematopoietic stem cell transplantation for sickle cell anemia. Pediatr Blood Cancer. 2015; 62(7):1277-84. DOI: 10.1002/pbc.25446. View

11.

Vlachos A, Rosenberg P, Atsidaftos E, Alter B, Lipton J . Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Blood. 2012; 119(16):3815-9. PMC: 3335385. DOI: 10.1182/blood-2011-08-375972. View

12.

Vlachos A, Muir E . How I treat Diamond-Blackfan anemia. Blood. 2010; 116(19):3715-23. PMC: 2981532. DOI: 10.1182/blood-2010-02-251090. View

13.

Hamilton J, Hutson S, Moser R, Kobrin S, Frohnmayer A, Alter B . Sources of uncertainty and their association with medical decision making: exploring mechanisms in Fanconi anemia. Ann Behav Med. 2013; 46(2):204-16. DOI: 10.1007/s12160-013-9507-5. View

14.

Rosenberg P, Alter B, Ebell W . Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica. 2008; 93(4):511-7. DOI: 10.3324/haematol.12234. View

15.

Sonnenberg F, Beck J . Markov models in medical decision making: a practical guide. Med Decis Making. 1993; 13(4):322-38. DOI: 10.1177/0272989X9301300409. View

16.

Legare F, Witteman H . Shared decision making: examining key elements and barriers to adoption into routine clinical practice. Health Aff (Millwood). 2013; 32(2):276-84. DOI: 10.1377/hlthaff.2012.1078. View

17.

Rosenbaum L . The Paternalism Preference--Choosing Unshared Decision Making. N Engl J Med. 2015; 373(7):589-92. DOI: 10.1056/NEJMp1508418. View

18.

Peffault de Latour R, Porcher R, Dalle J, Aljurf M, Korthof E, Svahn J . Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood. 2013; 122(26):4279-86. DOI: 10.1182/blood-2013-01-479733. View

19.

Giri N, Batista D, Alter B, Stratakis C . Endocrine abnormalities in patients with Fanconi anemia. J Clin Endocrinol Metab. 2007; 92(7):2624-31. DOI: 10.1210/jc.2007-0135. View

20.

Briggs A, Sculpher M . An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998; 13(4):397-409. DOI: 10.2165/00019053-199813040-00003. View